GLP-1 Medications May Quiet the Craving Behind Addiction
A landmark BMJ study published June 3, 2026 found that GLP-1 receptor agonists like semaglutide significantly reduced both the development and severity of substance use disorders in over 600,000 U.S. veterans. Cannabis use disorder risk dropped 14%,…
The No-Hunger Games- How GLP-1 Medication Adoption Is Changing Consumer Food Dem
GLP-1 medications lead to significant reductions in grocery spending, particularly in calorie-dense foods. This impact persists during medication use but reverses upon discontinuation.
Converging neurotrophic-immune signaling in autism spectrum disorder
This review examines the role of four interconnected signaling pathways in autism spectrum disorder. Among them, IGF-1 shows clinical trial support, while others remain preclinical or mechanistic.
GLP-1 therapies- an emerging approach for alcohol reduction?
A recent study found that semaglutide significantly reduced heavy drinking days and alcohol craving in adults with alcohol use disorder and obesity, offering a promising new approach.
Metabolic Health Explained
Metabolic health explained means understanding how the body manages energy through appetite regulation, insulin sensitivity, and blood sugar control. This guide clarifies metabolic dysfunction and insulin resistance in plain English. It also explains how…
Tirzepatide vs Liraglutide Clinical Research Comparison
This article provides a liraglutide vs tirzepatide clinical comparison focusing on their distinct mechanisms and efficacy in weight management. Tirzepatide shows superior weight loss outcomes compared to liraglutide in clinical trials. Understanding…
